The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive impairment (MCI) or mild-to-moderate Alzheimer's Disease (AD). The primary hypothesis (Part 1) is that at a generally well tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is \>0.3 nanomolar (nM).
Age range
50 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants Who Experience At Least One Adverse Event (AE)
Timeframe: Up to approximately 297 days
Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 57 days
Serum Area Under the Concentration-Time Curve of MK-2214 from Time 0 to 28 Hours (AUC0-28) After First and Third Dose
Timeframe: At designated time points (up to 85 days)
Serum Maximum Concentration (Cmax) of MK-2214 After First and Third Dose
Timeframe: At designated time points (up to 85 days)
Serum Time to Maximum Concentration (Tmax) of MK-2214 After First and Third Dose
Timeframe: At designated time points (up to 85 days)
Serum Apparent Terminal Half-Life (t1/2) of MK-2214 After First and Third Dose
Timeframe: At designated time points (up to 85 days)
Concentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 85 (C85d)
Timeframe: Day 85
Percentage change from baseline to Day 29 in free phospho-tau in CSF
Timeframe: Baseline and Day 29 pre-dose
Percentage change from baseline to Day 85 in free phospho-tau in CSF
Timeframe: Baseline and Day 85